AllianceBernstein’s Cytek Biosciences CTKB Stock Holding History

AllianceBernstein’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$616K	Hold	141,048	–	–	﹤0.01%	2611
2026 Q1	$712K	Hold	141,048	–	–	﹤0.01%	2476
2025 Q4	$712K	Sell	141,048 -8,600	-6%	-$39.9K	﹤0.01%	2484
2025 Q3	$519K	Sell	149,648 -2,200	-1%	-$8.26K	﹤0.01%	2652
2025 Q2	$516K	Hold	151,848	–	–	﹤0.01%	2623
2025 Q1	$609K	Hold	151,848	–	–	﹤0.01%	2472
2024 Q4	$985K	Sell	151,848 -644	-0.4%	-$3.84K	﹤0.01%	2338
2024 Q3	$845K	Hold	152,492	–	–	﹤0.01%	2404
2024 Q2	$851K	Buy	152,492 +51,340	+51%	+$308K	﹤0.01%	2393
2024 Q1	$679K	Buy	101,152 +644	+0.6%	+$5.09K	﹤0.01%	2452
2023 Q4	$917K	Hold	100,508	–	–	﹤0.01%	2309
2023 Q3	$555K	Sell	100,508 -12,913	-11%	-$104K	﹤0.01%	2519
2023 Q2	$969K	Buy	113,421 +12,913	+13%	+$116K	﹤0.01%	2305
2023 Q1	$924K	Hold	100,508	–	–	﹤0.01%	2268
2022 Q4	$1.03M	Hold	100,508	–	–	﹤0.01%	2255
2022 Q3	$1.48M	Hold	100,508	–	–	﹤0.01%	2077
2022 Q2	$1.08M	Buy	100,508 +2,200	+2%	+$21.9K	﹤0.01%	2301
2022 Q1	$1.06M	Buy	+98,308	New	+$1.33M	﹤0.01%	2411

Other funds holding CTKB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

AllianceBernstein's CTKB Position: Q2 2026 in Review

AllianceBernstein held its Cytek Biosciences (CTKB) position steady in Q2 2026 at 141,048 shares worth $616K. The position accounts for ﹤0.01% of the portfolio, ranked #2611.

AllianceBernstein first reported a position in CTKB in Q1 2022 and has held it in 18 quarters since. The position peaked at $1.48M in Q3 2022. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

AllianceBernstein held 141,048 shares of Cytek Biosciences worth $616K as of Q2 2026.
AllianceBernstein left its Cytek Biosciences share count unchanged in Q2 2026.
Cytek Biosciences made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #2611 holding.
AllianceBernstein first reported a position in Cytek Biosciences in Q1 2022 and has held it in 18 quarters since.
AllianceBernstein's Cytek Biosciences position peaked at $1.48M in Q3 2022.
155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.